-
Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 15, 2025 -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common
- 김갑성 기자
- 2025-07-15 04:05
-
LABCONNECT APPOINTS MITCHELL BLUMENFELD AS CHIEF FINANCIAL OFFICER
JOHNSON CITY, Tenn., July 15, 2025 -- LabConnect is pleased to announce the appointment of Mitch Blumenfeld as its Chief Financial Officer, effective August 4, 2025. Mitch joins LabConnect with proven experience as Chief Financial Officer for high-growth companies in multiple industries including pharmaceutical services, wholesale pharmaceutical distribution, and diversified manufacturing and consumer products. With over three decades of leadership experience, Mitchell brings extensive expertise in corporate financial management and strategic development. Before joining LabCon
- 황정호 기자
- 2025-07-15 02:56
-
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands Anticipate approximately $345 million in annualized EBITDA synergies by 2
- 김갑성 기자
- 2025-07-14 19:00
-
Zepp Health Corporation to Report Second Quarter 2025 Financial Results on August 3, 2025
Earnings Call Scheduled for 9:30 p.m. ET on August 3, 2025 MILPITAS, Calif., July 14, 2025 -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its second quarter 2025 unaudited financial results on Sunday, August 3, 2025. Management will hold a conference call at 9:30 p.m. Eastern Time on Sunday, August 3, 2025. Listeners may access the call by dialing: US (Toll Free): +1-888-346-8982
- 김갑성 기자
- 2025-07-14 19:00
-
AXA Announces Sammi Cheng as Brand Ambassador
[ 메디채널 황정호 기자 ] Empowering fearlessness through proactive planning and comprehensive protection HONG KONG, July 14, 2025 -- AXA Hong Kong and Macau ("AXA") is delighted to announce the return of award-winning actress and singer Sammi Cheng as its Brand Ambassador. This renewed collaboration underscores AXA's ongoing commitment to inspire individuals to embrace fearlessness by taking charge of their future through proactive planning and protecting what truly matters – with AXA as their trusted partner every step of the way. This collaboration has just debuted with a
- 황정호 기자
- 2025-07-14 15:55
-
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14, 2025 -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB
- 김갑성 기자
- 2025-07-14 15:38
-
Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports, demonstrating the high sensitivity of its Bridge Capture™ technology for mutation profiling in cell free DNA of metastatic colorectal cancer patients. Study shows that Bridge Capture™ matches the sensitivi
- 김갑성 기자
- 2025-07-14 15:00
-
Bridge Capture™, 대장암 액체 생검 파일럿 연구에서 확장 가능한 고감도 분석 기술 입증
사이언티픽 리포트 (Scientific Reports)에 게재된 임상 연구, Bridge Capture™로 전이성 대장암 환자의 혈액 샘플에서 주요 돌연변이 검출 투르쿠, 핀란드, 2025년 7월 14일 -- 차세대 염기서열분석을 위한 간소화된 표적 라이브러리 전처리 기술을 선도하는 생명공학 기업 지노밀 헬스(Genomill Health)가 Bridge Capture™ 기술의 높은 민감도를 입증한 임상 파일럿 연구 결과를 과학 저널 '사이언티픽 리포트(Scientific Reports)'에 발표했다. 이번 연구는 전이성 대장암 환자의 세포 유리 DNA(cell-free DNA)를 분석하여, Bridge Capture™가 미세방울 디지털 PCR(ddPCR)과 동등한 민감도로 돌연변이를 검출할 수 있음을 보여줬다. ddPCR은 해당 분야의 '골드 스탠더드'로 평가받는 기술이다. Bridge Capture™는 무제한 확장 가능한 유전자 패널, 간단하고 비용 효율적인 워크플로를 통해 분산형 NGS 검사를 가능하게 한다는 점에서 큰 주목을 받고 있다. 이 연구는 아리 리스티매키(Ari Ristimäki) 교수 그룹
- 김갑성 기자
- 2025-07-14 15:00
-
MGI Tech Won Green World Award for Sustainable Contribution to Thai Mangroves Conservation Efforts
AUCKERLAND, New Zealand, July 14, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to announce that it has been awarded the Green World Champion in the Environmental Improvement: Conservation & Wildlife Projects sector of Green World Award 2025. This award recognizes MGI's groundbreaking efforts in utilizing genomics technology to support the conservation of Thai mangrove species. MGI's collaboration with the Thai National Omics Center aims to introduce genetic diversity in
- 김갑성 기자
- 2025-07-14 14:11
-
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
[ 메디채널 김갑성 기자 ] Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive type of blood cancer First patient remains cancer free at 15 months and ongoing with additional patients having durable responses at 2, 5, and 11 months+ and durability data continuing to mature Patients in the trial have previously failed at
- 김갑성 기자
- 2025-07-14 12:43
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-09-04_THU
- 심코프, SimCorp Alternatives로 사모시장 투자 혁신 추진 00:16
- Global Times: China's V-Day commemorations showcase resolve, commitment to safeguarding peace 00:05
2025-09-03_WED
- 코벤트리, 앨런 부어거, 아바커스 소 기각 신청 22:44
- FNZ Appoints Ryan Beach as Group Head of North America and Peter Hiom as Group Head of Markets 22:25
- Switzerland Champions Design Innovation, Precision and Integrity as Business of Design Week 2026 Partner Country 21:59
- Midea、FC Barcelonaの新たなメインパートナーになる 21:26
- Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development 21:15
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 09월 04일 01시 50분